Pompano Beach, Fla., Dec. 09, 2015 (GLOBE NEWSWIRE) -- DS Healthcare Group’s flagship products are now selling in Walmart, one of Brazil’s largest retailers. With this addition, DS Laboratories further expands its global retail footprint as part of the company’s omni-channel approach and continued dedication to delivering its breakthroughs to consumers worldwide.
Brazilian customers can view our product selection and order at the following link: https://www.walmart.com.br/busca/?ft=ds+laboratories&PS=20
Brazil remains the world's third largest consumer market for toiletries and stands as the world’s second largest market for men’s and children’s hair care products. The partnership with Walmart is expected to drive significant revenue growth for the company in Brazil.
About DS Healthcare Group
DS Healthcare Group Inc. is a leader in the development of biotechnology for topical therapies. It markets through online channels, specialty retailers, distributors, pharmacies, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com or www.facebook.com/DS.Labs
Forward-looking statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov
Investor Relations DS Healthcare Group (888) 404-7770 ext. 3 [email protected]


Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 



